Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab
JNCI: Journal of the National Cancer Institute · 2026
DOI: 10.1093/jnci/djaf385 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2026. Verfasst von Giulia Maddalena und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben. Gefördert von: CPRIT Research Training.
Abstract (Originalsprache)
Background
Clinical benefit from later lines of therapy in metastatic colorectal cancer (mCRC) is limited. Patient selection for treatment is crucial for optimal risk-benefit evaluation. Codon-specific KRAS mutations have been implicated as predictive biomarkers for efficacy of trifluridine/tipiracil (TAS-102). However, their predictive impact for TAS-102 plus Bevacizumab (TAS-Bev), the new standard of care in mCRC, is unknown.
Methods
This large patient-based, real-world, retrospective cohort study of mCRC patients who received TAS-102 alone or in combination with bevacizumab between January 1, 2020, and March 1, 2023. A sensitivity analysis was performed in 2 independent cohorts from MD Anderson Cancer Center, Houston, TX, and Tempus AI, Inc., Chicago, IL, prior to polling the data together.
Results
A total of 946 mCRC patients were evaluated; KRAS was mutated in 57.8% cases, 39.4% involving G12 codon, and 9.8% G13. We found no association of KRAS-G12 mutations with overall survival (hazard ratio [HR] = 1.1, 95% confidence interval [CI] = 0.90 to 1.25; P = .441) on TAS-102 contradicting the reported predictive impact of these biomarkers. Moreover, we reported inferior overall survival for KRAS-G13 mutant patients (HR = 1.3, 95% CI = 1.02 to 1.69; P = .045). On TAS-Bev, no association was found between KRAS-G12 (HR = 0.8, 95% CI = 0.59 to 1.11; P = .188) or KRAS-G13 (HR = 1.66, 95% CI = 0.99 to 2.79; P = .072) mutations and overall survival.
Conclusions
No significant associations between KRAS-G12 and overall survival were found for TAS-102 or TAS-Bev. Further research is needed to assess the impact of these mutations on combined TAS-Bev therapy prior to any clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
- Oncology Unit 1, Veneto Institute of Oncology-IRCCS, Padova, Italy.
- Tempus AI, Inc, Chicago, IL, United States.
- Pharmacy Clinical Programs U.T. M.D. Anderson Cancer Center, Houston, TX, United States.
ORCID-Profile: Giulia Maddalena, Ymke van der Pol, Oscar E Villarreal, Oluwadara Coker, Hey Min Lee, Zach Rivers, Wendy Covert, Stacy Diao, Sara Lonardi, Jane E Rogers, Arvind Dasari, Justin Guinney, Scott Kopetz, Kanwal Raghav
Förderung
- CPRIT Research Training
Zitieren
APA
Maddalena, G., van der Pol, Y., Villarreal, O. E., Coker, O., Min Lee, H., Rivers, Z., Covert, W., Diao, S., Lonardi, S., Rogers, J. E., Dasari, A., Guinney, J., Kopetz, S., & Raghav, K. (2026). Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf385
Vancouver
Maddalena G, van der Pol Y, Villarreal OE, Coker O, Min Lee H, Rivers Z, et al. Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djaf385
BibTeX
@article{Maddalena2026,
author = {Maddalena, Giulia and van der Pol, Ymke and Villarreal, Oscar E and Coker, Oluwadara and Min Lee, Hey and Rivers, Zach and Covert, Wendy and Diao, Stacy and Lonardi, Sara and Rogers, Jane E and Dasari, Arvind and Guinney, Justin and Kopetz, Scott and Raghav, Kanwal},
title = {Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2026},
doi = {10.1093/jnci/djaf385}
}
EUVIMED